Booster dose: India’s pharma sector expected to grow 6-8% YoY in FY23


India’s Pharmaceuticals Market (IPM) is expected to grow 6-8% on a YoY basis in FY23.

As a result, growth was capped due to a high base effect and inventory hoarding in FY21 due to the disruption in supply of key raw materials caused by Covid-19.

Additionally, API (Active Pharmaceuticals Ingredient) business is expected to post high single-digit growth in FY23 due to higher demand, overall revenue growth is expected to be 9-10% year-on-year.

In a research note, India Ratings and Research (Ind-Ra) said it maintained a neutral outlook for the Indian pharmaceutical sector for FY23.

The agency said higher capital expenditure instead of the production-linked incentive program (PLI) would restrict the quantum of free cash flow generation during the year.

“Large players are sufficiently capitalized to make larger investments to adapt to the ongoing fundamental shift in market opportunities,” the note said.

“Cost reduction measures remain a priority for Indian businesses. However, intermediate disruptions such as high raw material costs and logistics expenses will put pressure on the level of free cash flow generated.”

Additionally, the agency said that with the significant improvement in free cash flow generated in the near term, M&A activity will continue to provide an inorganic boost in FY23.

“Ind-Ra does not expect industry liquidity to face a major risk, despite similar maturity levels in FY23 and FY24. Large pharma companies typically have large cash balances, which generally represent 14 to 16% of their income.

In addition, most companies have ample flexibility under covenants and diversified funding sources.

“Coverage of big pharma interests is likely to increase as scale and margins expand.”

“Ind-Ra expects big pharma to continue their healthy debt-funded investment and research and development program given greater visibility in terms of sales growth and profitability.”



(Only the title and image of this report may have been edited by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear reader,

Business Standard has always endeavored to provide up-to-date information and commentary on developments that matter to you and that have wider political and economic implications for the country and the world. Your constant encouragement and feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these challenging times stemming from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative opinions and incisive commentary on relevant topical issues.
However, we have a request.

As we battle the economic impact of the pandemic, we need your support even more so that we can continue to bring you more great content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.

Support quality journalism and subscribe to Business Standard.

digital editor


Comments are closed.